vTv Therapeutics (NASDAQ:VTVT) Coverage Initiated by Analysts at HC Wainwright

Research analysts at HC Wainwright initiated coverage on shares of vTv Therapeutics (NASDAQ:VTVT - Get Free Report) in a research note issued on Wednesday, MarketBeat.com reports. The firm set a "buy" rating and a $36.00 price target on the biotechnology company's stock. HC Wainwright's price objective suggests a potential upside of 87.11% from the company's previous close. HC Wainwright also issued estimates for vTv Therapeutics' Q1 2025 earnings at ($0.73) EPS, Q2 2025 earnings at ($0.91) EPS, Q3 2025 earnings at ($1.08) EPS, Q4 2025 earnings at ($1.24) EPS, FY2025 earnings at ($3.97) EPS, FY2026 earnings at ($3.57) EPS, FY2027 earnings at ($3.94) EPS, FY2028 earnings at ($3.67) EPS and FY2029 earnings at ($2.70) EPS.

Separately, StockNews.com began coverage on vTv Therapeutics in a research note on Thursday, March 27th. They set a "sell" rating for the company.

vTv Therapeutics Price Performance

NASDAQ VTVT traded up $0.47 on Wednesday, reaching $19.24. The company had a trading volume of 2,874 shares, compared to its average volume of 23,037. The firm has a 50-day moving average of $17.93 and a 200-day moving average of $15.78. The firm has a market capitalization of $61.38 million, a PE ratio of -4.25 and a beta of 0.81. vTv Therapeutics has a 1 year low of $12.12 and a 1 year high of $29.19.

vTv Therapeutics (NASDAQ:VTVT - Get Free Report) last posted its quarterly earnings data on Thursday, March 20th. The biotechnology company reported ($0.55) earnings per share for the quarter, beating analysts' consensus estimates of ($0.87) by $0.32. The firm had revenue of $0.02 million during the quarter.

Institutional Investors Weigh In On vTv Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of VTVT. Geode Capital Management LLC raised its holdings in shares of vTv Therapeutics by 12.9% during the fourth quarter. Geode Capital Management LLC now owns 11,634 shares of the biotechnology company's stock worth $158,000 after purchasing an additional 1,327 shares during the period. JPMorgan Chase & Co. acquired a new stake in vTv Therapeutics during the fourth quarter worth about $25,000. Finally, FMR LLC bought a new position in vTv Therapeutics in the third quarter worth about $2,402,000. Institutional investors own 17.51% of the company's stock.

vTv Therapeutics Company Profile

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.